1.24
-0.0036(-0.29%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.18 |
| Day High | 1.24 |
| Day Low | 1.18 |
| 52-Week High | 1.9 |
| 52-Week Low | 0.52 |
| Volume | 1.83M |
| Average Volume | 4.65M |
| Market Cap | 386.15M |
| PE | -5.62 |
| EPS | -0.22 |
| Moving Average 50 Days | 1.47 |
| Moving Average 200 Days | 1 |
| Change | -0 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $5.51 as of November 14, 2025 at a share price of $1.236. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 5 years ago, it would be worth $4,353.52 as of November 14, 2025 at a share price of $1.236.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Oct 23, 2025 11:30 AM GMT
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcas
Ocugen to Present at Industry and Investor Conferences in October 2025
GlobeNewswire Inc.
Oct 02, 2025 11:30 AM GMT
MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present at the 2025
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
GlobeNewswire Inc.
Sep 15, 2025 10:03 AM GMT
Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen to manufacture and supply OCU400 M